文献速递糖尿病

二甲双胍预防坦桑尼亚HIV感染者空腹血糖受损或糖耐量受损(糖尿病前期)人群糖尿病的II期随机安慰剂对照试验

Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial.
PubMed 文献 · Diabetologia · 2023-07-18

在坦桑尼亚开展的一项II期双盲安慰剂对照试验,纳入364例HIV合并糖尿病前期的成人,随机接受缓释二甲双胍2000mg/日或安慰剂治疗12个月。结果显示两组血糖均随时间下降,但12个月时组间无显著差异;二甲双胍组体重显著低于安慰剂组,且安全性良好。

要点

  • 12个月时二甲双胍组与安慰剂组空腹血糖均值差为-0.08 mmol/l(95%CI -0.37, 0.20),2小时血糖均值差为0.20 mmol/l(95%CI -0.17, 0.58),均无显著差异。
  • 二甲双胍组体重较安慰剂组显著降低,均值差为-1.47 kg(95%CI -2.58, -0.35)。
  • 二甲双胍组严重不良事件或死亡16/182(8.8%),安慰剂组18/182(9.9%),均与研究药物无关或不太可能相关。

核心结论

  • 在12个月随访期间,二甲双胍组和安慰剂组的血糖均随时间下降,但两组间无显著差异。
  • 二甲双胍治疗在HIV合并糖尿病前期个体中被认为是安全的。
  • 需要更大规模、更长随访的试验来确定二甲双胍能否安全用于HIV感染者预防糖尿病。

研究设计与样本

  • II期双盲安慰剂对照随机试验,在坦桑尼亚达累斯萨拉姆的医院招募≥18岁、HIV治疗稳定且存在糖尿病前期(空腹血糖受损和/或糖耐量受损)的成人。
  • 受试者于2019年11月4日至2020年7月21日随机接受缓释二甲双胍2000 mg/日或匹配安慰剂,随机化采用置换区组,分配隐藏于试验数据库。
  • 共随机化364例参与者(二甲双胍组182例,安慰剂组182例),随访12个月,主要结局为75 g葡萄糖负荷后2小时毛细血管血糖,采用意向性分析。

主要发现

  • 入组时二甲双胍组和安慰剂组平均空腹血糖分别为6.37 mmol/l(95%CI 6.23, 6.50)和6.26 mmol/l(95%CI 6.15, 6.36),平均2小时血糖分别为8.39 mmol/l(95%CI 8.22, 8.56)和8.24 mmol/l(95%CI 8.07, 8.41)。
  • 12个月最终评估时,二甲双胍组145/182(79.7%)与安慰剂组158/182(86.8%)报告过去28天内服药超过95%(p=0.068)。
  • 12个月时二甲双胍组和安慰剂组平均空腹血糖分别为6.17 mmol/l(95%CI 6.03, 6.30)和6.30 mmol/l(95%CI 6.18, 6.42),平均2小时血糖分别为7.88 mmol/l(95%CI 7.65, 8.12)和7.71 mmol/l(95%CI 7.49, 7.94)。
  • 线性混合模型控制基线值后,二甲双胍组与安慰剂组空腹血糖均值差为-0.08 mmol/l(95%CI -0.37, 0.20),2小时血糖均值差为0.20 mmol/l(95%CI -0.17, 0.58)。
  • 二甲双胍组体重显著低于安慰剂组,调整基线值后体重均值差为-1.47 kg(95%CI -2.58, -0.35)。

关键数值与推荐

  • 糖尿病前期定义为空腹血糖受损和/或糖耐量受损。
  • 主要结局为75 g葡萄糖负荷后2小时毛细血管血糖。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更大规模、更长随访的试验来确定二甲双胍能否安全用于HIV感染者预防糖尿病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: In sub-Saharan Africa (SSA), 5% of adults are living with type 2 diabetes and this is rising sharply, with a greater increase among people with HIV. Evidence on the efficacy of prevention strategies in this cohort is scarce. We conducted a Phase II double-blind placebo-controlled trial that aimed to determine the impact of metformin on blood glucose levels among people with prediabetes (defined as impaired fasting glucose [IFG] and/or impaired glucose tolerance [IGT]) and HIV in SSA. METHODS: Adults (≥18 years old) who were stable in HIV care and found to have prediabetes (IFG and/or IGT) and who were attending hospitals in Dar es Salaam, Tanzania, were randomised to receive sustained-release metformin, 2000 mg daily, or matching placebo between 4 November 2019 and 21 July 2020. Randomisation used permuted blocks. Allocation was concealed in the trial database and made visible only to the Chief Pharmacist after consent was taken. All participants, research and clinical staff remained blinded to the allocation. Participants were provided with information on diet and lifestyle and had access to various health information following the start of the coronavirus disease 2019 (COVID-19) pandemic. Participants were followed up for 12 months. The primary outcome measure was capillary blood glucose measured 2 h following a 75 g glucose load. Analyses were by intention-to-treat. RESULTS: In total, 364 participants (182 in each arm) were randomised to the metformin or placebo group. At enrolment, in the metformin and placebo arms, mean fasting glucose was 6.37 mmol/l (95% CI 6.23, 6.50) and 6.26 mmol/l (95% CI 6.15, 6.36), respectively, and mean 2 h glucose levels following a 75 g oral glucose load were 8.39 mmol/l (95% CI 8.22, 8.56) and 8.24 mmol/l (95% CI 8.07, 8.41), respectively. At the final assessment at 12 months, 145/182 (79.7%) individuals randomised to metformin compared with 158/182 (86.8%) randomised to placebo indicated that they had taken >95% of their medicines in the previous 28 days (p=0.068). At this visit, in the metformin and placebo arms, mean fasting glucose levels were 6.17 mmol/l (95% CI 6.03, 6.30) and 6.30 mmol/l (95% CI 6.18, 6.42), respectively, and mean 2 h glucose levels following a 75 g oral glucose load were 7.88 mmol/l (95% CI 7.65, 8.12) and 7.71 mmol/l (95% CI 7.49, 7.94), respectively. Using a linear mixed model controlling for respective baseline values, the mean difference between the metformin and placebo group (metformin-placebo) was -0.08 mmol/l (95% CI -0.37, 0.20) for fasting glucose and 0.20 mmol/l (95% CI -0.17, 0.58) for glucose levels 2 h post a 75 g glucose load. Weight was significantly lower in the metformin arm than in the placebo arm: using the linear mixed model adjusting for baseline values, the mean difference in weight was -1.47 kg (95% CI -2.58, -0.35). In total, 16/182 (8.8%) individuals had a serious adverse event (Grade 3 or Grade 4 in the Division of Acquired Immunodeficiency Syndrome [DAIDS] adverse event grading table) or died in the metformin arm compared with 18/182 (9.9%) in the placebo arm; these events were either unrelated to or unlikely to be related to the study drugs. CONCLUSIONS/INTERPRETATION: Blood glucose decreased over time in both the metformin and placebo arms during the trial but did not differ significantly between the arms at 12 months of follow up. Metformin therapy was found to be safe for use in individuals with HIV and prediabetes. A larger trial with longer follow up is needed to establish if metformin can be safely used for the prevention of diabetes in people who have HIV. TRIAL REGISTRATION: The trial is registered on the International Standard Randomised Controlled Trial Number (ISRCTN) registry ( www.isrctn.com/ ), registration number: ISCRTN76157257. FUNDING: This research was funded by the National Institute for Health Research using UK aid from the UK Government to support global health research.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Garrib A, Kivuyo S, Bates K, et al. Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial. Diabetologia. 2023. PMID: 37460828. doi:10.1007/s00125-023-05968-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。